February, 2025

article thumbnail

Boosting evolution: How humans unintentionally altered the skulls of pigs

Science Daily: Pharmacology News

Short snouts and a flat profile -- within a span of 100 years, humans have significantly changed the shape of the skulls of German domestic pigs. This is likely down to new breeding practices introduced at the beginning of the 20th century. The researchers analyzed 3D scans of 135 skulls of wild boars and domestic pigs from the early 20th and 21st centuries.

article thumbnail

Site-Specific Molecular Glues for the 14-3-3/Tau pS214 ProteinProtein Interaction via Reversible Covalent Imine Tethering

Covalent Modifiers

DOI Ansgar Oberheide, Maxime van den Oetelaar, Jakob Scheele, Jan Borggrfe, Semmy Engelen, Michael Sattler, Christian Ottmann, Peter Cossar and Luc Brunsveld RSC Med Chem 2025 [link] Protein-protein interactions (PPIs) are key regulators of various cellular processes. Modulating PPIs with small molecules has gained increasing attention in drug discovery, particularly targeting the 14-3-3 protein family, which interacts with several hundred client proteins and plays a central role in cellular net

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Analyzing Oxygen Atom Distribution in FDA‐Approved Drugs to Enhance Drug Discovery Strategies

Chemical Biology and Drug Design

Analysis of prevalence of ring, nonring, sp 3 -, and sp 2 -hybridized oxygen in approved drugs. For the first time, analysis of distribution of different types of oxygen from center of mass of a molecule. ABSTRACT Despite advancements in molecular design rules and understanding biochemical processes, the field of drug design and discovery seeks to minimize the number and duration of synthesis-testing cycles to convert lead compounds into drug candidates.

article thumbnail

New cell therapy model accelerates cancer treatment development

Drug Target Review

In the rapidly advancing field of cell therapies, Dr Jason Bock has emerged as a leader, known for his innovative approach to optimising the development process. With over 25 years of experience in therapeutics, Bock has played a pivotal role in shaping the future of cell therapies, particularly through his work at CTMC. In a recent conversation, he shared his vision for transforming the development and commercialisation of novel cell therapies, focusing on cutting-edge approaches like tumour in

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

AI-Designed Enzymes

Codon

One of the ultimate aims of protein design has long been to build entirely new enzymes — proteins that perform specific chemical reactions — from scratch. These molecular machines power various cellular processes, from converting sugar into energy to switching genes on and off. Both Cas9 and hydrolases (widely used in the dairy and laundry industries) are also enzymes.

article thumbnail

Streamlining the Generic Drug Supply Chain: Best Practices

Drug Patent Watch

Streamlining the Generic Drug Supply Chain: Best Practices to Improve Efficiency and Patient Access As the generic drug industry continues to grow, it's becoming increasingly clear that the traditional supply chain model is no longer sustainable. With the rise of complex generics, regulatory pressures, and increasing demand for affordable medicines, it's time to rethink the way we approach the generic drug supply chain.

More Trending

article thumbnail

Site-specific activation of the proton pumpinhibitor rabeprazole by tetrathiolate zinccentres

Covalent Modifiers

Teresa Marker, Raphael R. Steimbach, Cecilia Perez-Borrajero, Marcin Luzarowski, Eric Hartmann, Sibylle Schleich, Daniel Pastor-Flores, Elisa Espinet, Andreas Trumpp, Aurelio A. Teleman, Frauke Grter, Bernd Simon, Aubry K. Miller & Tobias P. Dick Nat. Chem. ( 2025 ). [link] Proton pump inhibitors have become top-selling drugs worldwide. Serendipitously discovered as prodrugs that are activated by protonation in acidic environments, proton pump inhibitors inhibit stomach acid secretion by cov

article thumbnail

Biochemical and Structural Studies of Protein Tyrosine Phosphatase PTP‐PEST (PTPN12) in Search of Small Molecule Inhibitors

Chemical Biology and Drug Design

An in-house molecule library was screened using in silico molecular docking, and a myo-inositol derivative was identified as a potent hit molecule. The invitro biochemical assays validated that J1-65 inhibits PTP-PEST activity competitively and the inhibitor binding stabilizes the protein-ligand complex. ABSTRACT PTP-PEST (also known as PTPN12) regulates cellular signaling and transduction pathways by dephosphorylating its substrate.

article thumbnail

How FSP Solutions Support Risk-Based Methodologies and Tech Innovation in Clinical Operations

PPD

Biopharmaceutical, biotech and medical device developers can choose from a range of options to support effective clinical operations across critical functions such as clinical monitoring, site management, clinical oversight, support services and site engagement. In the past, these developers mostly used in-house resources for their clinical monitoring and site management capabilities, whereas today they often prefer functional service provider (FSP) or full-service outsourcing (FSO) models, or a

article thumbnail

Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development

Alta Sciences

Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development pmjackson Wed, 02/19/2025 - 21:30 The unique physicochemical properties of oligonucleotides require the use of specialized bioanalytical approaches, with key considerations including selectivity and specificity, sensitivity, stability, and matrix effects. Addressing these factors means bioanalytical methods can effectively differentiate oligonucleotides from endogenous nucleic acids and metabolites, quantify low concentratio

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Remix vs. Next.js: A Comprehensive Look at Modern React Frameworks

Perficient: Drug Development

In the ever-evolving landscape of web development, choosing the right framework can significantly impact the performance and user experience of your applications. Two of the most prominent frameworks in the React ecosystem today areRemixandNext.js. Both are designed to enhance web development efficiency and performance, but they cater to different needs and use cases.

article thumbnail

Models show intensifying wildfires in a warming world due to changes in vegetation and humidity; only a minor role for lightning

Science Daily: Pharmacology News

Climate scientists present a realistic supercomputer simulation that resolves the complex interactions between fire, vegetation, smoke and the atmosphere. The authors find that increasing greenhouse gas emissions will likely increase the global lightning frequency by about 1.6% per degree Celsius global warming, with regional hotspots in the eastern United States, Kenya, Uganda and Argentina.

article thumbnail

Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers

Covalent Modifiers

James Cregg, Kristof Pota, Aidan C. A. Tomlinson, Jason Yano, Abby Marquez, Yang Liu, Christopher J. Schulze, Kyle J. Seamon, Matthew Holderfield, Xing Wei, Yongxian Zhuang, Yu Chi Yang, Jingjing Jiang, Yue Huang, Ruiping Zhao, Yun Ling, Zhican Wang, Michael Flagella, Zhengping Wang, Mallika Singh, John E. Knox, Robert Nichols, David Wildes, Jacqueline A.

article thumbnail

An ancient RNA-guided system could simplify delivery of gene editing therapies

Broad Institute

An ancient RNA-guided system could simplify delivery of gene editing therapies By Corie Lok February 27, 2025 Breadcrumb Home An ancient RNA-guided system could simplify delivery of gene editing therapies The programmable proteins are compact, modular, and can be directed to modify DNA in human cells. By Jennifer Michalowski, McGovern Institute February 27, 2025 Credit: Max Wilkinson The Tas protein uses an RNA guide to recognize a specific target DNA sequence.

RNA
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

In Uncertain Times, Good Compliance and Quality Communication Habits Can Offer a Port in the Storm

FDA Law Blog: Biosimilars

By John W.M. Claud The ongoing DOGE-led reductions to the federal workforce and recent sweeping policy changes have spawned many questions for compliance officers and quality managers in FDA-regulated companies. How will the cuts at FDA impact inspections and enforcement? Will there be a heightened appetite for mergers and acquisitions in the space?

article thumbnail

Target Analysis

Sygnature Discovery

Discerning the best route to a new drug candidate can often be illuminated by building a comprehensive knowledge of a target in order to choose the best approach for a drug discovery project. Our CADD experts adopt a comprehensive target analysis approach to develop an optimal hit finding strategy and ultimately to design better, selective compounds.

article thumbnail

Your Digital Accessibility Game Plan for eCommerce

Perficient: Drug Development

Global ecommerce brands delivering accessible user experiences to web and mobile users have an advantage over non-competitive brands. For starters, savvy brands recognize a largely untapped market segment consumers with disabilities and consumers over the age of 65. However, theres a misconception about these two consumer segments: they have limited spending power.

article thumbnail

New lipid nanoparticle platform delivers mRNA to the brain through the blood-brain barrier

Science Daily: Pharmacology News

Scientists have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature of the blood-brain barrier. The findings demonstrate the potential of this technology to pave the way for future treatments for a wide range of conditions such as Alzheimer's disease, amyotrophic lateral sclerosis, brain cancer, and drug addiction.

RNA
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Structural Basis for Substrate Binding, Catalysis and Inhibition of Breast Cancer Target Mitochondrial Creatine Kinase by Covalent Inhibitor via Cryo-EM

Covalent Modifiers

Merve Demir,*, Laura Koepping, Ya Li, Lynn Fujimoto, Andrey Bobkov, Jianhua Zhao, Taro Hitosugi, Eduard Sergienko Structure, 2024 [link] Mitochondrial creatine kinases (MtCKs) are key players in maintaining energy homeostasis in cells that work with cytosolic creatine kinases for energy transport from mitochondria to cytoplasm. The inhibition of breast cancer growth by cyclocreatine targeting CKs indicates dependence of cancer cells on the energy shuttle for cell growth and survival.

article thumbnail

Why brain cancer is often resistant to immunotherapy

Broad Institute

Why brain cancer is often resistant to immunotherapy By Allessandra DiCorato February 26, 2025 Breadcrumb Home Why brain cancer is often resistant to immunotherapy Researchers find four coordinated gene expression programs in immune cells from glioma tumors, including two that could lead to immunotherapy resistance. By Allessandra DiCorato February 26, 2025 Credit: Case courtesy of Dr.

article thumbnail

CRISPR 101: Cytosine and Adenine Base Editors

addgene Blog

Early CRISPR applications were often limited by the low editing efficiency of homology-directed repair (HDR) , the pathway for resolving DNA double-strand breaks (DSBs) preferred by researchers. Compared to non-homologous end joining (NHEJ) , HDR occurs at a relatively low frequency, especially in nondividing cells. Scientists everywhere wistfully imagined being able to specify and correct single-base mutations without introducing DSBs at all.

DNA
article thumbnail

How to Manage Generic Drug Development Timelines: Strategies for Success

Drug Patent Watch

Accelerating Generic Drug Development: Strategies for Success As a pharmaceutical professional, you know how crucial it is to navigate the complex landscape of generic drug development. With the increasing demand for affordable medications, generic drug manufacturers are under pressure to expedite their development timelines without compromising on quality.

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

How to Automate Content Updates Using AEM Groovy Scripts

Perficient: Drug Development

As an AEM author, updating existing page content is a routine task. However, manual updates, like rolling out a new template, can become tedious and costly when dealing with thousands of pages. Fortunately, automation scripts can save the day. Using Groovy scripts within AEM can streamline the content update process, reducing time and costs. In this blog, we’ll outline the key steps and best practices for using Groovy scripts to automate content updates.

article thumbnail

The Importance of Social Media Monitoring in Pharma

thought leadership

In today's digital age, social media has transformed how businesses communicate with their audiences. For pharmaceutical companies, this shift presents both challenges and opportunities. Social media can significantly enhance brand visibility and patient engagement and have an impact on the overall healthcare sector. Social media can significantly enhance brand visibility, patient engagement, and have an impact on the overall healthcare sector in this dynamic landscape.

article thumbnail

Identification of Covalent Cyclic Peptide Inhibitors Targeting Protein–Protein Interactions Using Phage Display

Covalent Modifiers

Sijie Wang, Franco F. Faucher, Matilde Bertolini, Heeyoung Kim, Bingchen Yu, Li Cao, Katharina Roeltgen, Scott Lovell, Varun Shanker, Scott D. Boyd, Lei Wang, Ralf Bartenschlager, and Matthew Bogyo Journal of the American Chemical Society 2025 DOI: 10.1021/jacs.4c15843 Peptide macrocycles are promising therapeutics for a variety of disease indications due to their overall metabolic stability and potential to make highly selective binding interactions with targets.

article thumbnail

MPG Primer: Setting up a Biobank: Who? What? Why?

Broad Institute

MPG Primer: Setting up a Biobank: Who? What? Why? By admin February 13, 2025 Breadcrumb Home MPG Primer: Setting up a Biobank: Who? What? Why? The Primer on Medical and Population Genetics is a series of weekly lectures on genetics topics related to human populations and disease. Experts from across the Medical and Population Genetics community at the Broad Institute give in-depth introductions to research in human genetics through overviews of core concepts and practical tutorials on tools for

article thumbnail

The Use of Wearables in Clinical Trials

Quanticate

Wearable technologies have become a driving force in modern healthcare, transforming how data is collected, monitored, and analysed in clinical research. As patient-centric models gain traction, the integration of wearables in clinical trialsalongside sensors, digital biomarkers, and robust data managementhas emerged as a key driver of innovation. By providing continuous, real-time insights, these tools empower researchers to make informed decisions faster while also enhancing participant engage

article thumbnail

Protecting Your Drug Patent in Global Markets: Strategies and Challenges

Drug Patent Watch

Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. With the rise of international trade and the increasing complexity of patent laws, it's more challenging than ever to safeguard your intellectual property.

article thumbnail

From Cloud to Local: Effortlessly Import Azure SQL Databases

Perficient: Drug Development

With most systems transitioning to cloud-based environments, databases are often hosted across various cloud platforms. However, during the development cycle, there are occasions when having access to a local database environment becomes crucial, particularly for analyzing and troubleshooting issues originating in the production environment. Sometimes, it is necessary to restore the production database to a local environment to diagnose and resolve production-related issues effectively.

article thumbnail

Enhancing Your Experience: What to Expect From Us in 2025

PPD

Its important for your clinical research organization (CRO) to continually assess and invest in capabilities that help drive the success of your clinical program. There are three core areas we are strategically addressing this year. They include: 1. Upgrading our technology stack Weve prioritized targeted improvements and new systems and tools that drive innovation, enhance efficiency, and improve site and patient relationships.

article thumbnail

Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?

Covalent Modifiers

Hui Tao, Bo Yang, Atena Farhangian, Ke Xu, Tongtong Li, Zhong-Yin Zhang, and Jianing Li Journal of Medicinal Chemistry 2025 DOI: 10.1021/acs.jmedchem.4c02760 Covalent-allosteric inhibitors (CAIs) may achieve the best of both worlds: increased potency, long-lasting effects, and reduced drug resistance typical of covalent ligands, along with enhanced specificity and decreased toxicity inherent in allosteric modulators.

article thumbnail

Challenges in Clinical Development of Products for Rare Disease

thought leadership

Rare diseases are defined in the Orphan Drug Act as diseases or conditions that affect less than 200,000 people in the United States. There are over 7,000 rare diseases affecting more than 30 million people in the United States, and despite the FDA's approval of over 600 treatments for rare diseases since signing the Orphan Drug Act into law in 1983, most rare diseases still do not have a treatment.